EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Interpretable Machine Learning Algorithms Identify Inetetamab‐Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer

Ning Xie, Dehua Liao, Binliang Liu, Jiwen Zhang, Liping Liu, Gang Huang, Quchang Ouyang iD

Journal of Clinical Laboratory Analysis · 2024

DOI: 10.1002/jcla.25124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2024. Verfasst von Ning Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Cancer Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hos…. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Machine Learning. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hunan Cancer Hospital Climb Plan, Hunan Provincial Natural Scientific Foundation, the China Anti-Cancer Association HER2 target Chinese Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

HER2‐positive breast cancer (BC), a highly aggressive malignancy, has been treated with the targeted therapy inetetamab for metastatic cases. Inetetamab (Cipterbin) is a recently approved targeted therapy for HER2‐positive metastatic BC, significantly prolonging patients' survival. Currently, there is no established biomarker to reliably predict or assess the therapeutic efficacy of inetetamab in BC patients.

Methods

This study harnesses the power of metabolomics and machine learning to uncover biomarkers for inetetamab in BC therapy. A total of 23 plasma samples from inetetamab‐treated BC patients were collected and stratified into responders and nonresponders. Ultra‐high‐performance liquid chromatography‐quadrupole time‐of‐flight mass spectrometry was utilized to analyze the metabolites in blood samples. A combination of univariate and multivariate statistical analyses was employed to identify these metabolites, and their biological functions were then ascertained by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Finally, machine learning algorithms were employed to screen responsive biomarkers from all differentially expressed metabolites.

Results

Our finding revealed 6889 unique metabolites that were detected. Pathways like retinol metabolism, fatty acid biosynthesis, and steroid hormone biosynthesis were enriched for differentially expressed metabolites. Notably, two key metabolites associated with inetetamab response in BC were identified: FAPy‐adenine and 2‐Pyrocatechuic acid. There was some negative correlation between progress‐free survival (PFS) and their kurtosis content.

Conclusions

In summary, the identification of these two significant differential metabolites holds promise as potential biomarkers for evaluating and predicting inetetamab treatment outcomes in BC, ultimately contributing to the diagnosis of the disease and the discovery of prognostic markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBiomarkers, TumorMachine LearningHumansFemaleMetabolomicsMiddle AgedMetabolomeAlgorithms

Stichwörter der Autor:innen

breast cancerinetetamab therapymachine learningplasma metabolomicstherapeutic markers

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Breast Cancer Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.
  • Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.
  • Department of Orthopaedics, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.

ORCID-Profile: Quchang Ouyang

Förderung

  • Hunan Cancer Hospital Climb Plan
  • Hunan Provincial Natural Scientific Foundation
  • the China Anti-Cancer Association HER2 target Chinese Research Fund

Zitieren

APA

Xie, N., Liao, D., Liu, B., Zhang, J., Liu, L., Huang, G., & Ouyang, Q. (2024). Interpretable Machine Learning Algorithms Identify Inetetamab‐Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.25124

Vancouver

Xie N, Liao D, Liu B, Zhang J, Liu L, Huang G, et al. Interpretable Machine Learning Algorithms Identify Inetetamab‐Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer. Journal of Clinical Laboratory Analysis. 2024. doi:10.1002/jcla.25124

BibTeX
@article{Xie2024,
  author = {Xie, Ning and Liao, Dehua and Liu, Binliang and Zhang, Jiwen and Liu, Liping and Huang, Gang and Ouyang, Quchang},
  title = {Interpretable Machine Learning Algorithms Identify Inetetamab‐Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer},
  journal = {Journal of Clinical Laboratory Analysis},
  year = {2024},
  doi = {10.1002/jcla.25124}
}
Kostenlos starten →